168 related articles for article (PubMed ID: 15104221)
21. [PTEN coding product: a marker for tumorigenesis and progression of endometrial carcinoma].
Gao QL; Ye F; Li J; Xing H; Lu YP; Ma D
Ai Zheng; 2003 Jun; 22(6):640-4. PubMed ID: 12948417
[TBL] [Abstract][Full Text] [Related]
22. Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth.
Lee JS; Choi YD; Choi C; Lee MC; Park CS; Min KW
Anal Quant Cytol Histol; 2005 Aug; 27(4):202-10. PubMed ID: 16220831
[TBL] [Abstract][Full Text] [Related]
23. Single mutations of the PTEN gene in recurrent ovarian carcinomas.
Schöndorf T; Dostal A; Grabmann J; Göhring UJ
J Soc Gynecol Investig; 2000; 7(5):313-6. PubMed ID: 11035285
[TBL] [Abstract][Full Text] [Related]
24. [An approach to early genetic alterations in precancerous cells].
Sato N; Nishida M; Noguchi M
Hum Cell; 2000 Sep; 13(3):103-8. PubMed ID: 11197771
[TBL] [Abstract][Full Text] [Related]
25. [Mutation, loss of heterozygosity, and expression of tumor suppressor gene ING1 in sporadic colorectal carcinoma].
Wei JB; Chen LS; Gao F
Ai Zheng; 2005 Feb; 24(2):141-4. PubMed ID: 15694021
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer.
McDaid HM; Cairns MT; Atkinson RJ; McAleer S; Harkin DP; Gilmore P; Johnston PG
Br J Cancer; 1999 Feb; 79(5-6):933-9. PubMed ID: 10070893
[TBL] [Abstract][Full Text] [Related]
27. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.
Freihoff D; Kempe A; Beste B; Wappenschmidt B; Kreyer E; Hayashi Y; Meindl A; Krebs D; Wiestler OD; von Deimling A; Schmutzler RK
Br J Cancer; 1999 Feb; 79(5-6):754-8. PubMed ID: 10070865
[TBL] [Abstract][Full Text] [Related]
28. [PTEN expression and its significance in human primary hepatocellular carcinoma].
Wan XW; Wang HY; Jiang M; He YQ; Liu SQ; Cao HF; Qiu XH; Tang L; Wu MC
Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):490-2. PubMed ID: 12939185
[TBL] [Abstract][Full Text] [Related]
29. Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer.
Sato K; Tamura G; Tsuchiya T; Endoh Y; Sakata K; Motoyama T; Usuba O; Kimura W; Terashima M; Nishizuka S; Zou T; Meltzer SJ
Virchows Arch; 2002 Feb; 440(2):160-165. PubMed ID: 11964046
[TBL] [Abstract][Full Text] [Related]
30. [Loss and inactivation of PTEN/MMAC1/TEP1 gene in lung cancer].
Zhang L; Liu T; Liu H; Gao J; Gu C
Zhonghua Bing Li Xue Za Zhi; 2000 Apr; 29(2):85-8. PubMed ID: 11866895
[TBL] [Abstract][Full Text] [Related]
31. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer.
Su TH; Chang JG; Perng LI; Chang CP; Wei HJ; Wang NM; Tsai CH
Gynecol Oncol; 2000 Feb; 76(2):193-9. PubMed ID: 10637069
[TBL] [Abstract][Full Text] [Related]
32. Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability.
Fujii H; Matsumoto T; Yoshida M; Furugen Y; Takagaki T; Iwabuchi K; Nakata Y; Takagi Y; Moriya T; Ohtsuji N; Ohtsuji M; Hirose S; Shirai T
Hum Pathol; 2002 Apr; 33(4):421-8. PubMed ID: 12055677
[TBL] [Abstract][Full Text] [Related]
33. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
[TBL] [Abstract][Full Text] [Related]
34. PTEN and other tumor suppressor gene mutations as secondary genetic alterations in synovial sarcoma.
Saito T; Oda Y; Kawaguchi K; Takahira T; Yamamoto H; Tanaka K; Matsuda S; Sakamoto A; Iwamoto Y; Tsuneyoshi M
Oncol Rep; 2004 May; 11(5):1011-5. PubMed ID: 15069540
[TBL] [Abstract][Full Text] [Related]
35. The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.
Konopka B; Janiec-Jankowska A; Paszko Z; Goluda M
J Cancer Res Clin Oncol; 2004 Feb; 130(2):114-21. PubMed ID: 14663583
[TBL] [Abstract][Full Text] [Related]
36. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
Salvesen HB; Stefansson I; Kretzschmar EI; Gruber P; MacDonald ND; Ryan A; Jacobs IJ; Akslen LA; Das S
Int J Oncol; 2004 Dec; 25(6):1615-23. PubMed ID: 15547698
[TBL] [Abstract][Full Text] [Related]
37. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
38. [Genetic analysis of endometriosis and ovarian cancer].
Obata K; Hoshiai H
Nihon Rinsho; 2001 Jan; 59 Suppl 1():217-20. PubMed ID: 11235170
[No Abstract] [Full Text] [Related]
39. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
40. Hypermethylation of the PTEN gene in ovarian cancer cell lines.
Schöndorf T; Ebert MP; Hoffmann J; Becker M; Moser N; Pur S; Göhring UJ; Weisshaar MP
Cancer Lett; 2004 Apr; 207(2):215-20. PubMed ID: 15072831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
